Dec 20, 2016
US drug approvals are on track to drop by more than half in 2016 compared to 2015. The agency had approved 19 new drugs this year as of 9 December, putting it on track for its lowest yearly tally since 2007. The decline is made more dramatic by 2015’s bumper crop of approvals. The FDA approved 45 new drugs last year...
Read More...
Nov 29, 2016
EC grants marketing authorisation for Takeda’s Ninlaro capsules The European Commission (EC) has granted conditional marketing authorisation for Takeda Pharmaceutical’s Ninlaro capsules. The oral proteasome inhibitor is indicated in combination with lenalidomide and dexamethasone for adult patients with multiple mye...
Read More...
Oct 04, 2016
FDA Approves Janssen's STELARA for the Treatment of Adults With Moderately to Severely Active Crohn’s Disease Janssen Biotech Inc. received approval from the U.S. FDA for STELARA (ustekinumab), used for the treatment of moderately to severely active Crohn’s disease in adults (18 years or older). The drug is for the ...
Read More...
Sep 30, 2016
GW Pharmaceuticals, a UK based company, believes in growing its own cannabis plants, search for its ingredients and then come up with medicines that help the company in taking one more step towards approval of Epidiolex, as seen in the announcement of positive phase 3 trial results earlier this week. The drug is fo...
Read More...
Sep 27, 2016
US FDA grants approval for Novartis' Ilaris to treat Periodic Fever Syndromes Novartis received approval to market its Periodic Fever Syndrome drug Ilaris (cancakinumab). The drug targets the syndrome, and will be used to treat a group of diseases that cause serious recurrent fever and pathogenic inflammation throug...
Read More...
Sep 23, 2016
The Food and Drug Administration approved the recent controversial drug to treat Duchenne muscular Dystrophy, which is a rare disease that confines boys to wheelchairs and condemns them to an early death. The decision was made after months of debate between the Agency and Sarepta Therapeutics, regarding the evidence...
Read More...
Sep 07, 2016
Targeted treatment can become a reality for esophageal cancer, as a study opens door A group of researchers Scientists, funded by Cancer Research UK and Medical Research Council, have discovered that oesophageal cancer can be classified into three different subtypes, paving the way for testing targeted treatments ta...
Read More...
Sep 02, 2016
Game changing agent, Opdivo, on a threshold to change standard of care in squamous cell carcinoma of the head and neck (SCCHN) According to Dr. Robert Ferris, who is vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of ...
Read More...
Aug 18, 2016
Branded product portfolio of Shionogi acquired by Lupin Pharma giant Lupin entered into a strategic agreement when its Japanese subsidiary Kyowa Pharmaceutical Industry Co. purchased the product portfolio of Japan’s Shionogi & Co., Ltd. The agreement results in acquisition of 21 products long-listed, and the dea...
Read More...
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper